- Home
- MTX vs NAMS Comparison
MTX vs NAMS Comparison
Compare MTX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTX
- NAMS
- Stock Information
- Founded
- MTX 1968
- NAMS 2019
- Country
- MTX United States
- NAMS Netherlands
- Employees
- MTX N/A
- NAMS N/A
- Industry
- MTX Major Chemicals
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- MTX Industrials
- NAMS Health Care
- Exchange
- MTX Nasdaq
- NAMS Nasdaq
- Market Cap
- MTX 2.4B
- NAMS 2.7B
- IPO Year
- MTX 1992
- NAMS N/A
- Fundamental
- Price
- MTX $76.21
- NAMS $23.55
- Analyst Decision
- MTX Strong Buy
- NAMS Strong Buy
- Analyst Count
- MTX 1
- NAMS 7
- Target Price
- MTX $97.00
- NAMS $38.17
- AVG Volume (30 Days)
- MTX 167.7K
- NAMS 581.4K
- Earning Date
- MTX 02-06-2025
- NAMS 02-06-2025
- Dividend Yield
- MTX 0.58%
- NAMS N/A
- EPS Growth
- MTX 138.40
- NAMS N/A
- EPS
- MTX 4.71
- NAMS N/A
- Revenue
- MTX $2,124,900,000.00
- NAMS $33,594,000.00
- Revenue This Year
- MTX N/A
- NAMS $131.53
- Revenue Next Year
- MTX $5.22
- NAMS N/A
- P/E Ratio
- MTX $16.17
- NAMS N/A
- Revenue Growth
- MTX N/A
- NAMS 78.77
- 52 Week Low
- MTX $64.83
- NAMS $15.19
- 52 Week High
- MTX $90.30
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- MTX 49.70
- NAMS 44.17
- Support Level
- MTX $75.01
- NAMS $22.53
- Resistance Level
- MTX $77.33
- NAMS $26.71
- Average True Range (ATR)
- MTX 1.56
- NAMS 0.97
- MACD
- MTX 0.28
- NAMS -0.45
- Stochastic Oscillator
- MTX 78.79
- NAMS 23.89
About MTX Minerals Technologies Inc.
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into three segments based on product type. The specialty minerals segment, sells calcium carbonate, limestone, and talc, which is used in the paper, building materials, paint, automotive, and pharmaceutical industries. The refractories segment sells products for steel furnaces. The performance materials segment sells bentonite used in steel alloy casting and household products including cat litter. The majority of revenue comes from the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.